Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer

BACKGROUND: MammaPrint® is a microarray-based gene expression test cleared by the US Food and Drug Administration to assess recurrence risk in early-stage breast cancer, aimed to guide physicians in making neoadjuvant and adjuvant treatment decisions. The increase in the incidence of invasive lobula...

Descripción completa

Detalles Bibliográficos
Autores principales: Beumer, Inès J., Persoon, Marion, Witteveen, Anke, Dreezen, Christa, Chin, Suet-Feung, Sammut, Stephen-John, Snel, Mireille, Caldas, Carlos, Linn, Sabine, van ’t Veer, Laura J., Bernards, Rene, Glas, Annuska M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153320/
https://www.ncbi.nlm.nih.gov/pubmed/27980389
http://dx.doi.org/10.4137/BMI.S38435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153320/
https://www.ncbi.nlm.nih.gov/pubmed/27980389
http://dx.doi.org/10.4137/BMI.S38435

Ejemplares similares